Foghorn Therapeutics
FHTX
39 hedge funds and large institutions have $255M invested in Foghorn Therapeutics in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 20 increasing their positions, 4 reducing their positions, and 9 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 4
1.55% more ownership
Funds ownership: 63.34% → 64.88% (+1.5%)
13% less funds holding
Funds holding: 45 → 39 (-6)
17% less capital invested
Capital invested by funds: $307M → $255M (-$51.5M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.21M |
| 2 |
Morgan Stanley
New York
|
+$6.39M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.01M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$993K |
| 5 |
State Street
Boston,
Massachusetts
|
+$875K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$13.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.44M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$1.29M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$911K |
| 5 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$404K |
FHTX Hedge Fund Activity: Q2 2021 in Review
39 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q2 2021, worth a combined $255M — down 17% from $307M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of FHTX and 3 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 20 added.
The largest buyer was BlackRock, adding an estimated $7.21M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $13.2M sold.
- 39 institutional investors held Foghorn Therapeutics (FHTX) as of Q2 2021, down from 45 in Q1 2021.
- Funds reported $255M of Foghorn Therapeutics stock for Q2 2021, down 17% quarter-over-quarter.
- 3 funds opened new Foghorn Therapeutics positions in Q2 2021 and 9 closed out, a net change of -6 holders.
- The largest Foghorn Therapeutics buyer in Q2 2021 was BlackRock, an estimated $7.21M added.
- The largest Foghorn Therapeutics seller in Q2 2021 was Cormorant Asset Management, an estimated $13.2M sold.
Based on aggregated 13F filings for Q2 2021.